Skip to main content
Clinical Trials/NCT00190034
NCT00190034
Suspended
Phase 4

N-Acetylcysteine Protects Against Acute Renal Insult in Patients With Abnormal Renal Function Undergoing Cardiopulmonary Bypass.

Far Eastern Memorial Hospital1 site in 1 country60 target enrollmentJanuary 2005

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Cardiovascular Disease
Sponsor
Far Eastern Memorial Hospital
Enrollment
60
Locations
1
Primary Endpoint
Serum creatinine and blood urea nitrogen: before, 48 h and 5 days after the operation procedure.
Status
Suspended
Last Updated
17 years ago

Overview

Brief Summary

The purpose of this study is to determine whether N-acetylcysteine is effective in the prophylaxis of post-cardiopulmonary bypass acute renal impairment.

Detailed Description

BACKGROUND Reactive oxygen species have been shown to cause contrast-induced nephrotoxicity (CIN). According to previous studies, the N-acetylcysteine has been proved to be advantageous in the avoidance of CIN. We seek to evaluate the efficacy of the antioxidant N-acetylcysteine in limiting the nephrotoxicity after cardiovascular surgery with cardiopulmonary bypass. METHODS We will prospectively study 60 patients who will receive a cardiovascular surgery with cardiopulmonary bypass. Patients will be randomly assigned to receive either N-acetylcysteine (600 mg orally twice daily for 4 doses) with 0.45% saline intravenously, before and after cardiopulmonary bypass, or placebo with 0.45% saline. Serum creatinine and blood urea nitrogen will be measured before, 48 h and 5 days after the operation procedure. Expected results Prophylactic oral administration of the antioxidant N-acetylcysteine, along with hydration, will significantly reduce the acute renal damage induced by CPB in patients with chronic renal insufficiency that need cardiovascular procedures.

Registry
clinicaltrials.gov
Start Date
January 2005
End Date
June 2007
Last Updated
17 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • All patients who will received cardiac surgery with cardiopulmonary bypass

Exclusion Criteria

  • Dialyzed patients
  • Acute renal failure
  • Advanced left ventricular systolic dysfunction defined as left ventricular ejection fraction ≦ 35%.
  • Acute chronic obstructive lung disease or asthma exacerbation
  • Allergy to N-acetylcysteine

Outcomes

Primary Outcomes

Serum creatinine and blood urea nitrogen: before, 48 h and 5 days after the operation procedure.

Study Sites (1)

Loading locations...

Similar Trials